Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia
- PMID: 27863764
- PMCID: PMC5119662
- DOI: 10.1016/j.bjhh.2016.07.004
Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia
Erratum in
-
Erratum to "Diagnosis and treatment of chronic lymphocytic leukemia: Recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia" [Rev Bras Hematol Hemoter. 2016;38(4):346-357].Rev Bras Hematol Hemoter. 2017 Jan-Mar;39(1):93-94. doi: 10.1016/j.bjhh.2017.01.002. Rev Bras Hematol Hemoter. 2017. PMID: 28270360 Free PMC article. No abstract available.
Abstract
Chronic lymphocytic leukemia is characterized by clonal proliferation and progressive accumulation of B-cell lymphocytes that typically express CD19+, CD5+ and CD23+. The lymphocytes usually infiltrate the bone marrow, peripheral blood, lymph nodes, and spleen. The diagnosis is established by immunophenotyping circulating B-lymphocytes, and prognosis is defined by two staging systems (Rai and Binet) established by physical examination and blood counts, as well as by several biological and genetic markers. In this update, we present the recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia for the diagnosis and treatment of chronic lymphocytic leukemia. The following recommendations are based on an extensive literature review with the aim of contributing to more uniform patient care in Brazil and possibly in other countries with a similar social-economic profile.
Keywords: Chronic lymphocytic leukemia; Cytogenetics; Immunophenotyping; Prognosis; Staging.
Copyright © 2016 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Editora Ltda. All rights reserved.
Similar articles
-
Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment.Am J Hematol. 2019 Nov;94(11):1266-1287. doi: 10.1002/ajh.25595. Epub 2019 Oct 4. Am J Hematol. 2019. PMID: 31364186 Review.
-
Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation.Leukemia. 2002 Aug;16(8):1460-9. doi: 10.1038/sj.leu.2402584. Leukemia. 2002. PMID: 12145686
-
Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment.Am J Hematol. 2013 Sep;88(9):803-16. doi: 10.1002/ajh.23491. Am J Hematol. 2013. PMID: 23720127 Review.
-
Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment.Am J Hematol. 2015 May;90(5):446-60. doi: 10.1002/ajh.23979. Am J Hematol. 2015. PMID: 25908509 Review.
-
Relationship between the expression of CD25 and CD69 on the surface of lymphocytes T and B from peripheral blood and bone marrow of patients with chronic lymphocytic leukemia and established prognostic factors of this disease.Adv Clin Exp Med. 2018 Jul;27(7):987-999. doi: 10.17219/acem/74437. Adv Clin Exp Med. 2018. PMID: 29893517
Cited by
-
CD200 Expression in Diagnostic and Prognostic Assessment of Mature B Cell Lymphophoproliferative Neoplasms.Asian Pac J Cancer Prev. 2018 Dec 25;19(12):3383-3392. doi: 10.31557/APJCP.2018.19.12.3383. Asian Pac J Cancer Prev. 2018. PMID: 30583344 Free PMC article.
-
Expert consensus on the management of chronic lymphocytic leukaemia in Asia.Clin Exp Med. 2023 Oct;23(6):2895-2907. doi: 10.1007/s10238-023-01007-2. Epub 2023 Feb 16. Clin Exp Med. 2023. PMID: 36795237 Free PMC article.
-
Evaluation of Diagnostic Usefulness of CD200 Expression in B-cell Chronic Lymphoproliferative Disorders.Indian J Hematol Blood Transfus. 2023 Oct;39(4):684-690. doi: 10.1007/s12288-022-01622-1. Epub 2023 Jan 3. Indian J Hematol Blood Transfus. 2023. PMID: 37786819 Free PMC article.
-
Role of Sirtuins in the Pathobiology of Onco-Hematological Diseases: A PROSPERO-Registered Study and In Silico Analysis.Cancers (Basel). 2022 Sep 23;14(19):4611. doi: 10.3390/cancers14194611. Cancers (Basel). 2022. PMID: 36230534 Free PMC article. Review.
-
Prognostic value of CD20 antigen mediated immune checkpoint inhibition in patients with acute or chronic lymphocytic leukemia: A protocol for systematic review.Medicine (Baltimore). 2022 Feb 18;101(7):e28868. doi: 10.1097/MD.0000000000028868. Medicine (Baltimore). 2022. PMID: 35363193 Free PMC article.
References
-
- DeSantis C.E., Lin C.C., Mariotto A.B., Siegel R.L., Stein K.D., Kramer J.L. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64(4):252–271. - PubMed
-
- Yamamoto J.F., Goodman M.T. Patterns of leukemia incidence in the united states by subtype and demographic characteristics, 1997–2002. Cancer Causes Control. 2008;19(4):379–390. - PubMed
-
- Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29. - PubMed
-
- Lanasa M.C. Novel insights into the biology of CLL. Hematology Am Soc Hematol Educ Program. 2010;2010:70–76. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources